Driehaus Capital Management LLC Purchases 987,997 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Driehaus Capital Management LLC boosted its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 89.5% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,092,011 shares of the company’s stock after buying an additional 987,997 shares during the period. Driehaus Capital Management LLC owned approximately 2.08% of Centessa Pharmaceuticals worth $18,891,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Quarry LP acquired a new stake in Centessa Pharmaceuticals during the 4th quarter worth approximately $48,000. Sandia Investment Management LP acquired a new stake in Centessa Pharmaceuticals during the 2nd quarter worth approximately $90,000. Fred Alger Management LLC acquired a new stake in Centessa Pharmaceuticals during the 2nd quarter worth approximately $99,000. EntryPoint Capital LLC acquired a new stake in Centessa Pharmaceuticals during the 1st quarter worth approximately $109,000. Finally, Trexquant Investment LP acquired a new stake in Centessa Pharmaceuticals during the 4th quarter worth approximately $114,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Price Performance

Shares of CNTA opened at $15.79 on Friday. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -11.12 and a beta of 1.44. Centessa Pharmaceuticals plc has a 1-year low of $5.15 and a 1-year high of $17.59. The company’s fifty day simple moving average is $13.01 and its 200 day simple moving average is $10.84. The company has a current ratio of 13.29, a quick ratio of 13.29 and a debt-to-equity ratio of 0.27.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). On average, research analysts forecast that Centessa Pharmaceuticals plc will post -1.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Gregory M. Weinhoff sold 12,198 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $12.17, for a total transaction of $148,449.66. Following the transaction, the insider now directly owns 241,171 shares in the company, valued at $2,935,051.07. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, insider Gregory M. Weinhoff sold 12,198 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $12.17, for a total transaction of $148,449.66. Following the transaction, the insider now directly owns 241,171 shares in the company, valued at $2,935,051.07. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Gregory M. Weinhoff sold 25,000 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.00, for a total transaction of $375,000.00. Following the transaction, the insider now owns 223,369 shares in the company, valued at $3,350,535. The disclosure for this sale can be found here. Over the last three months, insiders have sold 288,492 shares of company stock worth $4,641,902. Insiders own 11.59% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on CNTA. Guggenheim raised their target price on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Jefferies Financial Group lifted their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $11.00 to $26.00 in a report on Thursday, September 19th. B. Riley started coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price objective on the stock. Finally, BMO Capital Markets lifted their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $25.17.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.